Pro-angiogenic activity of thyroid hormone analogues

Mechanisms, physiology and clinical prospects

Paul J. Davis, Faith B. Davis, Hung Yun Lin, Mary K. Luidens, Shaker A. Mousa

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Thyroid hormone and analogues have demonstrated potent pro-angiogenic activity in various in vitro and in vivo model systems. These pro-angiogenic effects of thyroid hormone are initiated nongenomically at a receptor on integrin αvβ3 on receptor blood vessel endothelial cells, but may culminate in genomic responses. This receptor on the cell surface may direct gene transcription and regulate activity of plasma membrane vascular growth factor receptors. Promotion of hormonal angiogenic activity can be blocked by tetrac and nanoparticulate tetrac that inhibit binding of T4 and T3 to αvβ3, and also block activities of endogenous vascular growth factors. Endogenous or prescribed thyroid hormone appears to support tumor-relevant angiogenesis. It may also support pathologic skin neovascularization. In the absence of malignancy, however, the angiogenic activity of the hormone has exhibited experimental utility in wound-healing and tissue ischemia. Clinical applications of the hormone may be optimized by a nanoparticulate to which the hormone is covalently bound. Nanoparticulate thyroid hormone does not gain access to the intracellular space and acts exclusively at the hormone receptor on integrin αvβ3. Restriction of the hormone to the extracellular space avoids unwanted hormonal effects on cellular respiration, on protein synthesis and on protein turnover and specific organ effects, such as cardiac tachyarrhythmias. Needed are more extensive preclinical data on the actions of thyroid hormone, T4 and T3 on, respectively, wound-healing and revascularization of limb or cardiac ischemic tissues.

Original languageEnglish
Title of host publicationAngiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets
PublisherSpringer Netherlands
Pages29-46
Number of pages18
ISBN (Print)9789400764675, 9400764669, 9789400764668
DOIs
Publication statusPublished - Nov 1 2013

Fingerprint

Thyroid Hormones
Hormones
Integrins
Wound Healing
Pathologic Neovascularization
Intracellular Space
Cell Respiration
Growth Factor Receptors
Extracellular Space
Cell Surface Receptors
Triiodothyronine
Thyroxine
Tachycardia
Blood Vessels
Neoplasms
Intercellular Signaling Peptides and Proteins
Proteins
Ischemia
Extremities
Endothelial Cells

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Davis, P. J., Davis, F. B., Lin, H. Y., Luidens, M. K., & Mousa, S. A. (2013). Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects. In Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets (pp. 29-46). Springer Netherlands. https://doi.org/10.1007/978-94-007-6467-5_4

Pro-angiogenic activity of thyroid hormone analogues : Mechanisms, physiology and clinical prospects. / Davis, Paul J.; Davis, Faith B.; Lin, Hung Yun; Luidens, Mary K.; Mousa, Shaker A.

Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands, 2013. p. 29-46.

Research output: Chapter in Book/Report/Conference proceedingChapter

Davis, PJ, Davis, FB, Lin, HY, Luidens, MK & Mousa, SA 2013, Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects. in Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands, pp. 29-46. https://doi.org/10.1007/978-94-007-6467-5_4
Davis PJ, Davis FB, Lin HY, Luidens MK, Mousa SA. Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects. In Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands. 2013. p. 29-46 https://doi.org/10.1007/978-94-007-6467-5_4
Davis, Paul J. ; Davis, Faith B. ; Lin, Hung Yun ; Luidens, Mary K. ; Mousa, Shaker A. / Pro-angiogenic activity of thyroid hormone analogues : Mechanisms, physiology and clinical prospects. Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands, 2013. pp. 29-46
@inbook{66d126ff380a4bdd8433cc592301ce04,
title = "Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects",
abstract = "Thyroid hormone and analogues have demonstrated potent pro-angiogenic activity in various in vitro and in vivo model systems. These pro-angiogenic effects of thyroid hormone are initiated nongenomically at a receptor on integrin αvβ3 on receptor blood vessel endothelial cells, but may culminate in genomic responses. This receptor on the cell surface may direct gene transcription and regulate activity of plasma membrane vascular growth factor receptors. Promotion of hormonal angiogenic activity can be blocked by tetrac and nanoparticulate tetrac that inhibit binding of T4 and T3 to αvβ3, and also block activities of endogenous vascular growth factors. Endogenous or prescribed thyroid hormone appears to support tumor-relevant angiogenesis. It may also support pathologic skin neovascularization. In the absence of malignancy, however, the angiogenic activity of the hormone has exhibited experimental utility in wound-healing and tissue ischemia. Clinical applications of the hormone may be optimized by a nanoparticulate to which the hormone is covalently bound. Nanoparticulate thyroid hormone does not gain access to the intracellular space and acts exclusively at the hormone receptor on integrin αvβ3. Restriction of the hormone to the extracellular space avoids unwanted hormonal effects on cellular respiration, on protein synthesis and on protein turnover and specific organ effects, such as cardiac tachyarrhythmias. Needed are more extensive preclinical data on the actions of thyroid hormone, T4 and T3 on, respectively, wound-healing and revascularization of limb or cardiac ischemic tissues.",
author = "Davis, {Paul J.} and Davis, {Faith B.} and Lin, {Hung Yun} and Luidens, {Mary K.} and Mousa, {Shaker A.}",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/978-94-007-6467-5_4",
language = "English",
isbn = "9789400764675",
pages = "29--46",
booktitle = "Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Pro-angiogenic activity of thyroid hormone analogues

T2 - Mechanisms, physiology and clinical prospects

AU - Davis, Paul J.

AU - Davis, Faith B.

AU - Lin, Hung Yun

AU - Luidens, Mary K.

AU - Mousa, Shaker A.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Thyroid hormone and analogues have demonstrated potent pro-angiogenic activity in various in vitro and in vivo model systems. These pro-angiogenic effects of thyroid hormone are initiated nongenomically at a receptor on integrin αvβ3 on receptor blood vessel endothelial cells, but may culminate in genomic responses. This receptor on the cell surface may direct gene transcription and regulate activity of plasma membrane vascular growth factor receptors. Promotion of hormonal angiogenic activity can be blocked by tetrac and nanoparticulate tetrac that inhibit binding of T4 and T3 to αvβ3, and also block activities of endogenous vascular growth factors. Endogenous or prescribed thyroid hormone appears to support tumor-relevant angiogenesis. It may also support pathologic skin neovascularization. In the absence of malignancy, however, the angiogenic activity of the hormone has exhibited experimental utility in wound-healing and tissue ischemia. Clinical applications of the hormone may be optimized by a nanoparticulate to which the hormone is covalently bound. Nanoparticulate thyroid hormone does not gain access to the intracellular space and acts exclusively at the hormone receptor on integrin αvβ3. Restriction of the hormone to the extracellular space avoids unwanted hormonal effects on cellular respiration, on protein synthesis and on protein turnover and specific organ effects, such as cardiac tachyarrhythmias. Needed are more extensive preclinical data on the actions of thyroid hormone, T4 and T3 on, respectively, wound-healing and revascularization of limb or cardiac ischemic tissues.

AB - Thyroid hormone and analogues have demonstrated potent pro-angiogenic activity in various in vitro and in vivo model systems. These pro-angiogenic effects of thyroid hormone are initiated nongenomically at a receptor on integrin αvβ3 on receptor blood vessel endothelial cells, but may culminate in genomic responses. This receptor on the cell surface may direct gene transcription and regulate activity of plasma membrane vascular growth factor receptors. Promotion of hormonal angiogenic activity can be blocked by tetrac and nanoparticulate tetrac that inhibit binding of T4 and T3 to αvβ3, and also block activities of endogenous vascular growth factors. Endogenous or prescribed thyroid hormone appears to support tumor-relevant angiogenesis. It may also support pathologic skin neovascularization. In the absence of malignancy, however, the angiogenic activity of the hormone has exhibited experimental utility in wound-healing and tissue ischemia. Clinical applications of the hormone may be optimized by a nanoparticulate to which the hormone is covalently bound. Nanoparticulate thyroid hormone does not gain access to the intracellular space and acts exclusively at the hormone receptor on integrin αvβ3. Restriction of the hormone to the extracellular space avoids unwanted hormonal effects on cellular respiration, on protein synthesis and on protein turnover and specific organ effects, such as cardiac tachyarrhythmias. Needed are more extensive preclinical data on the actions of thyroid hormone, T4 and T3 on, respectively, wound-healing and revascularization of limb or cardiac ischemic tissues.

UR - http://www.scopus.com/inward/record.url?scp=84931404949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931404949&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-6467-5_4

DO - 10.1007/978-94-007-6467-5_4

M3 - Chapter

SN - 9789400764675

SN - 9400764669

SN - 9789400764668

SP - 29

EP - 46

BT - Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets

PB - Springer Netherlands

ER -